Related Experiment Video
Updated: May 6, 2026
02:14
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
Published on: August 1, 2025
2.2K
[Update on non-variceal gastrointestinal bleeding]
1Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Universidad de Zaragoza, IIS Aragón, CIBERehd, Zaragoza, España.
Gastroenterologia Y Hepatologia
|October 29, 2013
Summary
Early endoscopy and proton pump inhibitors (PPIs) do not improve outcomes for gastrointestinal bleeding. Oral PPIs are as effective as IV PPIs post-hemostasis, and NSAID risks require careful consideration.
Area of Science:
- Gastroenterology
- Clinical Medicine
Context:
- Review of key studies presented at the 2013 American Congress of Gastroenterology (Digestive Disease Week).
- Focus on non-variceal gastrointestinal bleeding, addressing areas of clinical uncertainty.
Purpose:
- To summarize recent advancements and findings in non-variceal gastrointestinal bleeding.
- To highlight new knowledge regarding diagnostic and therapeutic strategies.
Summary:
- Early endoscopy (within 6 hours for UGIB, 24 hours for LGIB) and pre-endoscopic proton pump inhibitor (PPI) administration do not improve patient prognosis.
- Oral PPIs demonstrate comparable efficacy to intravenous PPIs following endoscopic hemostasis in upper gastrointestinal bleeding (UGIB).
- Radiofrequency ablation shows promise for treating antral vascular ectasia.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) and coxibs necessitate careful risk assessment (gastrointestinal and cardiovascular), especially when co-prescribed with other gastrotoxic agents.
- Environmental and genetic factors contribute to individual susceptibility to gastrointestinal bleeding.
Impact:
- Challenges current practices regarding early endoscopy and PPI use in gastrointestinal bleeding.
- Suggests a shift towards oral PPIs for post-hemostasis management.
- Emphasizes personalized risk assessment for NSAID/coxib prescribing.
- Highlights the multifactorial nature of gastrointestinal bleeding susceptibility.
Related Concept Videos
01:28Esophageal Varices-II: Clinical Features and Management
893
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
893
01:24Esophageal Varices-I: Introduction
2.4K
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
2.4K
01:25Peptic Ulcer Disease III: Clinical Manifestations and Complications
71
Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant...
71
01:23Gastritis III: Clinical Manifestations and Management
1.9K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.9K
01:24Peptic Ulcer Disease II: Pathophysiology
77
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
77
01:28Peptic Ulcer Disease II: Pathophysiology
3.0K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
3.0K